Emergence of small molecule non-RGD-mimetic inhibitors for RGD integrins

Lisa M. Miller, John M. Pritchard, Simon J. F. Macdonald, Craig Jamieson, Allan J. B. Watson

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)
154 Downloads (Pure)


The RGD integrins are recognized therapeutic targets for thrombosis, fibrosis, and cancer, amongst others. Current inhibitors are designed to mimic the tripeptide sequence (arginineglycine-aspartic acid) of the natural ligands; however, the RGD-mimetic antagonists for αIIbβ3 have been shown to cause partial agonism, leading to the opposite pharmacological effect. The challenge of obtaining oral activity and synthetic tractability with RGD-mimetic molecules, along with the issues relating to pharmacology, has left integrin-therapeutics in need of a new strategy. Recently, a new generation of inhibitor has emerged that lacks the RGD-mimetic. This 2 perspective will discuss the discovery of these non-RGD-mimetic inhibitors, and the progress that has been made in this promising new chemotype.
Original languageEnglish
Number of pages11
JournalJournal of Medicinal Chemistry
Issue number8
Early online date30 Jan 2017
Publication statusPublished - 30 Jan 2017


  • RGD integrins
  • therapeutic targets
  • tripeptide sequence
  • ligands
  • non-RGD-mimetic inhibitors
  • heterodimeric cell adhesion receptors
  • extracellular matrix


Dive into the research topics of 'Emergence of small molecule non-RGD-mimetic inhibitors for RGD integrins'. Together they form a unique fingerprint.

Cite this